San Francisco startup Composition Therapeutics is usually focusing on an oral, once-daily GLP-1 drug identified as GSBR-1290—the drug surpassed Wall Road’s anticipations in June any time a mid-phase review confirmed typical weight loss of close to 6% and it plans to start another mid-stage trial in the direction of the top of the 12 months—th